Filing Flows › Teva Pharmaceutical Industries (TEVA) › Q3 2026 › vs Q2 2026
Teva Pharmaceutical Industries (TEVA) Q3 2026 vs Q2 2026 (quarter over quarter)
Teva Pharmaceutical Industries's revenue rose $253M (+6%) from $4.1B in Q2 2026 to $4.4B in Q3 2026. The biggest changes: Sale of goods +$138M (+4%); Other +$114M (+163%); Distribution −$12.0M (-3%). Gross margin 55.5% against 52.0% (+3.5 pts).
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 55.5% | 52.0% | +3.5 pts |
| Operating margin | 16.2% | -5.6% | +21.8 pts |
| Net margin | 5.3% | -13.9% | +19.2 pts |
| Free cash flow margin | 2.8% | 7.4% | -4.7 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Sale of goods | $3.7B | $3.6B | $138M | +4% |
| Distribution | $421M | $433M | −$12.0M | -3% |
| Other | $184M | $70.0M | $114M | +163% |
| Licensing arrangements | $49.0M | $37.0M | $12.0M | +32% |
| Revenue | $4.4B | $4.1B | $253M | +6% |
| Gross profit | $2.4B | $2.2B | $287M | +13% |
| Cost of revenue | $2.0B | $2.0B | −$34.0M | -2% |
| Operating profit | $714M | −$231M | $945M | — |
| Operating expenses | $1.7B | $2.4B | −$658M | -28% |
| Pre-tax earnings | $300M | −$455M | $755M | — |
| Other expense, net | $414M | $224M | $190M | +85% |
| Research & development | $297M | $970M | −$673M | -69% |
| Sales & marketing | $709M | $717M | −$8.0M | -1% |
| General & admin | $298M | $317M | −$19.0M | -6% |
| Other operating costs | $422M | $380M | $42.0M | +11% |
| Net earnings | $234M | −$575M | $809M | — |
| Income tax | $66.0M | $121M | −$55.0M | -45% |
| Operating cash sources | $517M | −$294M | $811M | — |
| Depreciation & amortization | $245M | $241M | $4.0M | +2% |
| Share-based compensation | $38.0M | $40.0M | −$2.0M | -5% |
| Working capital & other | $276M | −$705M | $981M | — |
| Operating cash flow | $241M | $411M | −$170M | -41% |
| Free cash flow (OCF − capex) | $121M | $307M | −$186M | -61% |
| Capital expenditures | $120M | $104M | $16.0M | +15% |
Questions
How much did Teva Pharmaceutical Industries's revenue grow quarter over quarter in Q3 2026?
Teva Pharmaceutical Industries's revenue rose $253M (+6%) from $4.1B in Q2 2026 to $4.4B in Q3 2026.
What drove Teva Pharmaceutical Industries's revenue change in Q3 2026?
Sale of goods +$138M (+4%); Other +$114M (+163%); Distribution −$12.0M (-3%).